Esperion Therapeutics (ESPR) said Tuesday that its bempedoic acid has been submitted by Otsuka Pharmaceutical to the Japanese Ministry of Health, Labour, and Welfare for approval to treat hypercholesterolemia and familial hypercholesterolemia.
Esperion said the submission was based on preliminary results from a late-stage study, in which bempedoic acid showed statistical significance in reducing LDL-C compared to placebo.
Otsuka acquired exclusive development and commercialization rights for bempedoic acid in Japan from Esperion in 2020, Esperion said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments